METCURE THERAPEUTICS, LLC

Biotech · Private

GH501, a small-molecule inhibitor of Skp1-FBP interaction for metastatic castration-resistant prostate cancer

Grants
$2.5M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer$160,996
Federal grantDepartment of Health and Human Services · Phase I · Novel small-molecule targeted therapy for prostate cancer$224,999
Federal grantDepartment of Health and Human Services · Phase I · Small-molecule therapy for metastatic prostate cancer$224,999
Federal grantDepartment of Health and Human Services · Phase II · Small-molecule therapy for metastatic castration-resistant prostate cancer$1,007,817
Federal grantDepartment of Health and Human Services · Phase II · Small-molecule therapy for metastatic castration-resistant prostate cancer$927,358
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3112Cybrexa, Inc.——
3113GENERAL BIOLOGICS, INC.——
3114MONOMERCHEM, inc——
3115METCURE THERAPEUTICS, LLC——
3116PAMDECA, LLC——
3117ALLYX BIOSCIENCES, INC.——
3118PROTERIS BIOTECH, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.